📊 MDXG Key Takeaways
Is MDXG a Good Investment? Thesis Analysis
MiMedx demonstrates exceptional financial health with robust revenue growth of 20% YoY and impressive profitability metrics, including an 82.6% gross margin and 11.6% net margin. The company generates strong free cash flow of $72M with minimal leverage (0.07x debt/equity) and substantial cash reserves of $166.1M, indicating excellent capacity for reinvestment and financial flexibility.
Why Buy MDXG? Key Strengths
- Exceptional liquidity with 4.32x current ratio and $166.1M cash reserve
- Outstanding profitability with 82.6% gross margin and 18.9% ROE
- Strong organic growth of 20% revenue YoY with positive net income growth of 14.5%
- Excellent free cash flow generation at $72M (17.2% FCF margin) relative to net income
- Minimal financial leverage at 0.07x debt/equity with 188.5x interest coverage ratio
- High-quality earnings with 11.6% net margin demonstrating operational efficiency
MDXG Investment Risks to Consider
- Medical device sector exposure to regulatory changes and FDA compliance requirements
- Limited disclosure on customer concentration and competitive market dynamics
- Operating margin of 15.3% leaves room for improvement relative to gross margin potential
Key Metrics to Watch
- Revenue growth trajectory - monitor if 20% growth rate sustains or moderates
- Gross margin stability - watch for any compression from scale or mix changes
- Free cash flow conversion - ensure operating cash flow translates consistently to FCF
- Long-term debt levels - monitor capital allocation decisions and use of cash reserves
MDXG Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.32x current ratio provides a solid financial cushion.
MDXG Profitability Ratios
MDXG vs Healthcare Sector
How MIMEDX GROUP, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MDXG Overvalued or Undervalued?
Based on fundamental analysis, MIMEDX GROUP, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MDXG Balance Sheet & Liquidity
MDXG 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: MIMEDX GROUP, INC.'s revenue has grown significantly by 40% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.37 reflects profitable operations.
MDXG Growth Metrics (YoY)
MDXG Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $84.1M | $8.1M | $0.05 |
| Q2 2025 | $87.2M | $9.6M | $0.06 |
| Q1 2025 | $84.7M | $7.0M | $0.05 |
| Q3 2024 | $81.7M | $4.8M | $0.00 |
| Q2 2024 | $81.3M | $1.2M | $0.01 |
| Q1 2024 | $71.7M | -$5.0M | $-0.06 |
| Q3 2023 | $67.7M | $4.8M | $0.00 |
| Q2 2023 | $66.9M | $1.2M | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MDXG Capital Allocation
MDXG SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for MIMEDX GROUP, INC. (CIK: 0001376339)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773786746.xml | View → |
| Mar 17, 2026 | 4 | xslF345X05/wk-form4_1773786668.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773351421.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773351342.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773351285.xml | View → |
❓ Frequently Asked Questions about MDXG
What is the AI rating for MDXG?
MIMEDX GROUP, INC. (MDXG) has an AI rating of STRONG BUY with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MDXG's key strengths?
Claude: Exceptional liquidity with 4.32x current ratio and $166.1M cash reserve. Outstanding profitability with 82.6% gross margin and 18.9% ROE.
What are the risks of investing in MDXG?
Claude: Medical device sector exposure to regulatory changes and FDA compliance requirements. Limited disclosure on customer concentration and competitive market dynamics.
What is MDXG's revenue and growth?
MIMEDX GROUP, INC. reported revenue of $418.6M.
Does MDXG pay dividends?
MIMEDX GROUP, INC. does not currently pay dividends.
Where can I find MDXG SEC filings?
Official SEC filings for MIMEDX GROUP, INC. (CIK: 0001376339) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MDXG's EPS?
MIMEDX GROUP, INC. has a diluted EPS of $0.32.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MDXG a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MIMEDX GROUP, INC. has a STRONG BUY rating with 92% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is MDXG stock overvalued or undervalued?
Valuation metrics for MDXG: ROE of 18.9% (sector avg: 15%), net margin of 11.6% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy MDXG stock in 2026?
Our dual AI analysis gives MIMEDX GROUP, INC. a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MDXG's free cash flow?
MIMEDX GROUP, INC.'s operating cash flow is $74.0M, with capital expenditures of $2.0M. FCF margin is 17.2%.
How does MDXG compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 11.6% (avg: 12%), ROE 18.9% (avg: 15%), current ratio 4.32 (avg: 2).